NCT05124951
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Nov 2021); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
3-year event-free survival
Timeframe: From the enrollment to the event (relapse or death of any cause), approximately 3 years. The patients will receive long-term follow-up including MRI and serum tumor markers examination every 3 months until 36 months.
Change of score of the QoL questionnaire (PedsQL 4.0 : Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales, Chinese edition)
Timeframe: Score will be obtained at baseline, 6 months posttreatment, yearly through 3 years posttreatment
Change of score of the QoL questionnaire (Short form-36)
Timeframe: Evaluation will be conducted at baseline, 6 months posttreatment, yearly through 3 years posttreatment
Change of score of Chinese Wechsler Intelligence Scale for Children
Timeframe: Score will be obtained at baseline, 6 months posttreatment, yearly through 3 years posttreatment
Secondary (2)
3-year overall survival
Short-term adverse effects of treatments
Arms and interventions
iGCTSExperimental
Stratum I (Germinoma) Patients who achieved complete response after induction chemotherapy will receive WVI 2400cGy/15f plus primary boost 640cGy/4f. Stratum II (NGGCTs) At the time of response evaluation before radiotherapy, those with complete response or residue disease \<1.5cm will receive WVI 3060cGy/17f plus primary boost 2340cGy/13f.
Radiation: Whole-ventricle irradiation
Drugs: Carboplatin/etoposide, Ifosfamide/cisplatin/etoposide
Procedures: Second-look surgery
Sites
1 site in 1 country
- Beijing Tiantan HospitalBeijing, China